Fellow’s quick read · Infectious Diseases
Asymptomatic Bacteriuria
IDSA 2019 (Nicolle et al.) · reviewed 2026-08-10
Personal study digest for a new ID fellow. Recommendations are from the IDSA 2019 guideline (Nicolle LE et al., CID 2019;68(10):e83–e75, doi:10.1093/cid/ciy1121). The “What’s changed since 2019” section is reviewer synthesis of newer evidence, each claim cited. Not a substitute for the full guideline.
In one line
Treat ASB in exactly two populations: pregnant women and patients undergoing endourologic procedures with expected mucosal trauma. Everyone else — including the elderly, diabetics, catheterized patients, spinal cord injury, and renal transplant recipients >1 month — should not be screened or treated.◆What is asymptomatic bacteriuria?
- Definition: ≥105 CFU/mL of one or two bacterial species in a voided urine specimen, without signs or symptoms of urinary tract infection.
- Women: require two consecutive voided specimens with the same organism at ≥105 CFU/mL.
- Men: a single voided specimen at ≥105 CFU/mL suffices.
- Catheterized patients: a single specimen at ≥105 CFU/mL from a catheter in place ≥48 h.
- The mere presence of pyuria alongside ASB does not indicate symptomatic UTI and is not an indication for treatment. IDSA 2019, Rec I
◆Who NOT to screen or treat
The guideline’s dominant message is a list of populations where screening and treating ASB is actively harmful or wasteful:
| Population | Recommendation | Strength / Evidence |
|---|---|---|
| Healthy nonpregnant women | Do not screen or treat | Strong, moderate. Treatment may increase subsequent symptomatic UTI risk. |
| Older adults (community) | Do not screen or treat | Strong, moderate |
| Older adults (LTC) | Do not screen or treat | Strong, low. ASB prevalence 25–50% in LTC; treating drives resistance without benefit. |
| Delirium + bacteriuria (no GU symptoms) | Assess other causes of delirium; observe | Strong, very low. Bacteriuria is coincidental, not causal. |
| Falls + bacteriuria (no GU symptoms) | Assess other causes of falls; observe | Strong, very low |
| Diabetes | Do not screen or treat | Strong, moderate |
| Renal transplant >1 month | Do not screen or treat | Strong, HIGH. Strongest evidence in the guideline (Origüen RCT). |
| Nonrenal SOT | Do not screen or treat | Strong, moderate |
| Spinal cord injury | Do not screen or treat | Strong, low. ASB may actually be protective. |
| Short-term catheter (<30 d) | Do not screen or treat | Strong, low |
| Long-term catheter (>30 d) | Do not screen or treat | Strong, moderate |
| Children | Do not treat | Strong, low |
| Nonurologic surgery | Do not screen or treat | Strong, low. Includes orthopedic, cardiac, and vascular procedures. |
◆Who TO screen and treat
| Population | Action | Treatment | Strength |
|---|---|---|---|
| Pregnant women | Screen with urine culture at least once in early pregnancy | Treat with targeted antibiotics for 4–7 days (weak, low for duration). Follow up to confirm clearance. | Strong, moderate |
| Endourologic procedures with expected mucosal trauma | Screen with urine culture before the procedure | Targeted therapy preferred over empiric (weak, very low). 1–2 perioperative doses (weak, low) — not a full course. | Strong, moderate |
◆Key decisions a fellow owns
- The urine culture was sent — now what? A positive culture in a patient without UTI symptoms is ASB. The right answer in most patients is to stop: do not reflexively treat a lab result. Pyuria does not change this.
- Delirium in a nursing-home patient with a positive UA: Do not treat the bacteriuria. Investigate delirium’s actual cause (medications, constipation, pain, infection elsewhere). This is the single most common ASB-treatment error in hospital practice.
- Renal transplant consult: After the first month, do not screen for or treat ASB. This carries the highest-quality evidence in the entire guideline.
- Before a urologic procedure: Check whether mucosal trauma is expected. If yes, send a urine culture and give 1–2 perioperative doses of targeted therapy. If no mucosal trauma, treat as nonurologic surgery (do not screen).
- Pregnant patient: Screen and treat. Follow-up culture to confirm clearance. Duration 4–7 days. Untreated ASB in pregnancy carries 20–30% pyelonephritis risk.
◆Knowledge gaps flagged by the guideline
- High-risk neutropenia: No recommendation made — insufficient data. The guideline explicitly labels this a knowledge gap.
- ASB at catheter removal: No recommendation; unclear whether a culture at the time of catheter removal changes outcomes.
- Urologic device implantation: Suggest not treating (weak, very low) — evidence is thin.
- Renal transplant <1 month: Not directly addressed; most centers still screen and treat during the stented period (see “What’s changed”).
What’s changed since 2019
Reviewer synthesis of newer evidence — not the guideline. Each claim cited.
- No newer IDSA ASB guideline. The 2019 version remains the current IDSA recommendation as of August 2026. The IDSA guideline page lists no update.
- Renal transplant >1 month — now even stronger. Three systematic reviews and meta-analyses of RCTs (2023–2025) confirm no benefit of treating ASB in kidney transplant recipients: no reduction in symptomatic UTI (RR 1.05–1.19), no difference in pyelonephritis, graft loss, rejection, or mortality. One 2025 meta-analysis of 4 RCTs (478 patients) concluded: “Current evidence does not support routine screening and treatment of posttransplant ASB.” Aslan et al., OFID 2025 (doi:10.1093/ofid/ofaf502); Rao et al., Medicina 2023 (doi:10.3390/medicina59091600); Medina-Polo et al., Antibiotics 2024 (doi:10.3390/antibiotics13050442)
- Early post-transplant (<2 months) remains an evidence gap. A 2026 Canadian survey of nephrologists found 80% screen and 100% treat ASB during the first 2 months post-KT (while stented), despite absent evidence. 88% would participate in an RCT withholding antibiotics. This mirrors the IDSA guideline’s silence on the first month. Rodriguez-Ramirez et al., Clin Transplant 2026 (doi:10.1111/ctr.70529)
- Stewardship interventions remain difficult. A 2025 EHR-based intervention updating urinalysis/urine culture order set indications to match the IDSA guideline had no impact on ASB testing or treatment rates in older adults. Behavioral change is the bottleneck, not guideline clarity. Smith et al., ICHE 2025 (doi:10.1017/ice.2025.10296)
- Modified urine culture reporting is a promising strategy. An RCT of suppressing organism ID and susceptibilities on urine cultures from catheterized patients increased appropriate non-treatment of catheter-associated ASB (45% vs 33% untreated), with no safety signal. Pratt et al., ICHE 2021 (doi:10.1017/ice.2020.1397)
- International guidelines aligned. The EAU 2025, French MS Society 2020, Canadian PM&R Choosing Wisely 2023, and Argentine Intersociety 2020 guidelines all echo the IDSA position: treat ASB only in pregnancy and before invasive urologic procedures. Perepanova et al., Urologiia 2025 (PMID 42417340); Donzé et al., Rev Neurol 2020 (doi:10.1016/j.neurol.2020.02.011); Neferu et al., Am J Phys Med Rehabil 2025 (doi:10.1097/PHM.0000000000002599)
- Pregnancy ASB — still current. Cochrane 2019 update confirms treating ASB reduces pyelonephritis (RR 0.24), preterm birth (RR 0.34), and low birthweight (RR 0.64), though all with low-certainty evidence. No new RCTs change the recommendation. Smaill & Vazquez, Cochrane 2019 (doi:10.1002/14651858.CD000490.pub4)
- Still current: All other recommendations (older adults, delirium/falls, diabetes, SCI, catheterized patients, nonurologic surgery) remain unchanged and unchallenged by post-2019 data.
◆Anki cards minted this run
- ASB definition: specimen requirements differ by sex — women need 2 consecutive specimens, men need 1. Foundational diagnostic criterion. [core definition, board-relevant]
- Renal transplant >1 month: do not treat ASB — strongest evidence in the guideline (Origüen RCT), now reinforced by 3 meta-analyses (2023–2025). [currency layer, practice-changing]
- Delirium/falls + bacteriuria: bacteriuria is coincidental, not causal — assess other causes, observe. The most common ASB-treatment error in hospital practice. [stewardship pearl, high-yield]
Existing cards cover: indications to treat ASB (note 1690153859539), pregnancy ASB complications (notes 1614284832585, 1614284889705). Not duplicated.
Sources
- [1] Nicolle LE, Gupta K, Bradley SF, et al. Clinical practice guideline for the management of asymptomatic bacteriuria: 2019 update by the Infectious Diseases Society of America. Clin Infect Dis 2019;68(10):e83–e75. doi:10.1093/cid/ciy1121. PMID 30895288.
- [2] Aslan AT, Tanriverdi LH, Hernandez AV, et al. Effectiveness and safety of antibiotics in kidney transplant recipients with asymptomatic bacteriuria: a systematic review and meta-analysis of randomized controlled trials. Open Forum Infect Dis 2025;12(9):ofaf502. doi:10.1093/ofid/ofaf502. PMID 41018707.
- [3] Rao Z, Wang Z, Tang M, et al. Treatment of asymptomatic bacteriuria after kidney transplantation: a systematic review and meta-analysis of randomized controlled trials. Medicina (Kaunas) 2023;59(9):1600. doi:10.3390/medicina59091600. PMID 37763718.
- [4] Medina-Polo J, Falkensammer E, Köves B, et al. Systematic review and meta-analysis provide no guidance on management of asymptomatic bacteriuria within the first year after kidney transplantation. Antibiotics (Basel) 2024;13(5):442. doi:10.3390/antibiotics13050442. PMID 38786170.
- [5] Rodriguez-Ramirez S, Hall V, Husain S, et al. Asymptomatic bacteriuria in kidney transplant: approaches to screening and treatment — a national survey of Canadian nephrologists. Clin Transplant 2026;40(4):e70529. doi:10.1111/ctr.70529. PMID 41930786.
- [6] Smith EEA, Shay S, Phe K, et al. Assessing the impact of an electronic health record intervention on testing and treatment for asymptomatic bacteriuria in older adults. Infect Control Hosp Epidemiol 2025;46(12):1282–1284. doi:10.1017/ice.2025.10296. PMID 40963381.
- [7] Pratt CL, Rehan Z, Xing L, et al. Modified reporting of positive urine cultures to reduce inappropriate antibiotic treatment of catheter-associated asymptomatic bacteriuria among inpatients, a randomized controlled trial. Infect Control Hosp Epidemiol 2021;42(10):1221–1227. doi:10.1017/ice.2020.1397. PMID 34085614.
- [8] Smaill FM, Vazquez JC. Antibiotics for asymptomatic bacteriuria in pregnancy. Cochrane Database Syst Rev 2019;(11):CD000490. doi:10.1002/14651858.CD000490.pub4. PMID 31765489.